OUTSTAND-1 was a randomised, double-blind, placebo-controlled trial of safiglipron, a once-daily GLP-1 tablet, in people with type 2 diabetes taking no diabetes medicine. Over 32 weeks, HbA1c fell by up to 1.45 percentage points more than on placebo. The effect on body weight was modest.
Why it is interesting: An oral GLP-1 agonist tested against placebo in type 2 diabetes before any other treatment.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.
Other drivers in Health today
-
Cancer
Where is cancer incidence rising and falling, what screening and new tests find earlier, and what treatment has done to survival.
4 this week -
Obesity, diabetes and GLP-1
Are obesity and diabetes still rising, what behavioural change and public policy do, and what difference do GLP-1s and other similar drugs make.
2 this week -
Heart and stroke
Whether deaths from heart disease and stroke have stopped falling, what is found earlier, what treatment and prevention do now, and what the deaths say.
None this week Earlier → -
Mental health
Deaths by suicide, the life expectancy gap in severe mental illness, and the physical disease that follows it: what mental illness costs in lives.
1 this week -
Dementia
Whether dementia is becoming more or less common, what is now found, what treatment and prevention do, and what the deaths say.
1 this week -
Frailty and multimorbidity
Whether the years added after 85 are healthy ones, how frailty and multiple conditions are measured, and where the data run out.
1 this week
